Tsuda 2004.

Methods	Uncontrolled phase I/II study
Participants	14 patients with gynaecological cancer after primary therapy (ovarian cancer n = 5; NED n = 2)
Interventions	Subcutaneous individualised short peptide cocktail Adjuvant: Montanide ISA‐51
Outcomes	Tumour responses Immune responses: humoral, cellular Adverse events: not separately described for ovarian cancer patients
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Uncontrolled trial
Allocation concealment (selection bias)	High risk	Uncontrolled trial
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Selective reporting (reporting bias)	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Other bias	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’